Global Biomarker Collaboration and Licensing Partnering Analysis Report 2023 with Directory of 463 Deals Signed Since 2016
Wednesday, November 22, 2023
DUBLIN, Nov. 14, 2023 /PRNewswire/ -- The "Biomarker Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report contains a comprehensive listing of 463 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties.
Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter Highlights
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.
Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.
Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:
-- Understand deal trends since 2016
-- Browse biomarker collaboration and licensing deals
-- Benchmark analysis - identify market value of transactions
-- Financials terms - upfront, milestone, royalties
-- Directory of deals by company A-Z, deal type and therapy area
-- Leading deals by value
-- Most active dealmakers
-- Identify assets and deal terms for each transaction
-- Access contract documents - insights into deal structures
-- Due diligence - assess suitability of your proposed deal terms for
partner companies
-- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
-- What are the precise rights granted or optioned?
-- What is actually granted by the agreement to the partner company?
-- What exclusivity is granted?
-- What is the payment structure for the deal?
-- How are sales and payments audited?
-- What is the deal term?
-- How are the key terms of the agreement defined?
-- How are IPRs handled and owned?
-- Who is responsible for commercialization?
-- Who is responsible for development, supply, and manufacture?
-- How is confidentiality and publication managed?
-- How are disputes to be resolved?
-- Under what conditions can the deal be terminated?
-- What happens when there is a change of ownership?
-- What sublicensing and subcontracting provisions have been agreed?
-- Which boilerplate clauses does the company insist upon?
-- Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
-- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker deals over the years
2.3. Most active biomarker dealmakers
2.4. Biomarker deals by deal type
2.5. Biomarker deals by therapy area
2.6. Biomarker deals by industry sector
2.7. Deal terms for biomarker deals
2.7.1 Biomarker deals headline values
2.7.2 Biomarker deal upfront payments
2.7.3 Biomarker deal milestone payments
2.7.4 Biomarker royalty rates
Chapter 3 - Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value
Chapter 4 - Most active biomarker dealmakers
4.1. Introduction
4.2. Most active biomarker dealmakers
4.3. Most active biomarker deals company profiles
Chapter 5 - Biomarker contracts dealmaking directory
5.1. Introduction
5.2. Biomarker contracts dealmaking directory
Chapter 6 - Biomarker dealmaking by technology type
Deal directory
Deal directory - Biomarker deals by company A-Z
Deal directory - Biomarker deals by deal type
Deal directory - Biomarker deals by therapy area
Companies Mentioned
-- Medical University South Carolina
-- CytoVale
-- Australian Centre for Plant Functional Genomics
-- Australian Imaging
-- Food Allergy Research & Education
-- VirtualScopics
-- MDxHealth
-- GE Healthcare
-- Brigham and Women's Hospital
-- Beckman Coulter
-- Menssana Research
-- Bpifrance
-- RainDance Technologies
-- Asterand Bioscience
-- Lung and Blood Institute
-- Food and Drug Administration (FDA)
-- Rockland Immunochemicals
-- John and Lucille Van Geest Foundation
-- Bill and Melinda Gates Foundation
-- PierianDx
-- Quadrant Biosciences
-- Vigilant Biosciences
-- Guardant Health
-- Jubilant Therapeutics
-- Dominantly Inherited Alzheimers Network
-- Renovar
-- Stellar Biotechnologies
-- Biosearch Technologies
-- A Menarini Diagnostics
-- Metamark Genetics
-- The Parker Institute For Cancer Immunotherapy
-- 4D Pharma
-- Fluofarma
-- GC Pharma
-- Pharmaron
-- ImmunArray
-- LightArray Biotech
-- San Martino Hospital
-- Veravas
-- Tel Hashomer
-- GeneData
-- Medidata Solutions
-- CogState
-- Prostate Cancer Foundation (PCF)
-- Innovate UK
-- Pharmatech Solutions
-- Biocrates
-- QDx Pathology Services
For more information about this report visit https://www.researchandmarkets.com/r/kw2oqm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-biomarker-collaboration-and-licensing-partnering-analysis-report-2023-with-directory-of-463-deals-signed-since-2016-301988335.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
The Roadmap to Securing Your Own Digital Domain is Now Available | Jan 22, 2026
|
|
|
